Correction: Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor
===================================================================================================================


Chan J, Nguyen M, Cheong E, *et al*. Refractory Mycobacterium genavense infection secondary to thymoma-associated endogenous IL-12 inhibitor. *BMJ Neurol Open* 2022; 41: e000285. DOI:10.1136/bmjno-2022-000285

The article has been corrected since it was published online. The authors would like to notify that the co-author Dr. Hannah Hu was inadvertently omitted from the authorship list. Dr. Hu is affiliated to Department of Immunology, Concord Repatriation General Hospital, Concord, New South Wales, Australia.

Additionally, the contributors statement has been updated as follows.

**Contributors** JC contributed to acquisition of data and drafting the manuscript. MN contributed to conception of the work, acquisition of data, analysis and interpretation of data. HH contributed to experiment data and analysis. DSR, EC and SR contributed to conception of the work and interpretation of data. All authors contributed to revision of the manuscript for important intellectual content and approved the version to be published.

*   © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

[http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).